JP7287940B2 - ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物 - Google Patents

ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物 Download PDF

Info

Publication number
JP7287940B2
JP7287940B2 JP2020501430A JP2020501430A JP7287940B2 JP 7287940 B2 JP7287940 B2 JP 7287940B2 JP 2020501430 A JP2020501430 A JP 2020501430A JP 2020501430 A JP2020501430 A JP 2020501430A JP 7287940 B2 JP7287940 B2 JP 7287940B2
Authority
JP
Japan
Prior art keywords
cell
cells
linker
anchor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020501430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515288A5 (https=
JP2020515288A (ja
Inventor
ダッサン，スコット・ケイ
ピュリゲダ，ラマ・デヴドゥ
Original Assignee
ランケナウ・インスティテュート・フォー・メディカル・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ランケナウ・インスティテュート・フォー・メディカル・リサーチ filed Critical ランケナウ・インスティテュート・フォー・メディカル・リサーチ
Publication of JP2020515288A publication Critical patent/JP2020515288A/ja
Publication of JP2020515288A5 publication Critical patent/JP2020515288A5/ja
Application granted granted Critical
Publication of JP7287940B2 publication Critical patent/JP7287940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020501430A 2017-03-24 2018-03-23 ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物 Active JP7287940B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762476599P 2017-03-24 2017-03-24
US62/476,599 2017-03-24
US201762526608P 2017-06-29 2017-06-29
US62/526,608 2017-06-29
PCT/US2018/024073 WO2018175917A1 (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Publications (3)

Publication Number Publication Date
JP2020515288A JP2020515288A (ja) 2020-05-28
JP2020515288A5 JP2020515288A5 (https=) 2021-04-30
JP7287940B2 true JP7287940B2 (ja) 2023-06-06

Family

ID=63584730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020501430A Active JP7287940B2 (ja) 2017-03-24 2018-03-23 ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物

Country Status (7)

Country Link
US (2) US11946074B2 (https=)
EP (1) EP3601558A4 (https=)
JP (1) JP7287940B2 (https=)
CA (1) CA3056249A1 (https=)
IL (2) IL312457A (https=)
SG (2) SG11201908384XA (https=)
WO (1) WO2018175917A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908384XA (en) * 2017-03-24 2019-10-30 Lankenau Inst Medical Res Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
WO2020171020A1 (ja) * 2019-02-18 2020-08-27 株式会社エヌビィー健康研究所 細胞の選抜方法、核酸の製造方法、組換え細胞の製造方法、目的物質の製造方法、医薬組成物の製造方法、及び試薬

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520037A (ja) 2001-01-16 2004-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
US20110269152A1 (en) 2010-05-02 2011-11-03 Miltenyi Biotec Gmbh Anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell
JP2015536345A (ja) 2012-11-14 2015-12-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 組換え型の細胞表面捕捉タンパク質
US20150377887A1 (en) 2013-02-27 2015-12-31 Yu-Cheng Su In situ affinity maturation of antibodies
JP2016163574A (ja) 2015-03-06 2016-09-08 艾博生技抗体股▲ふん▼有限公司 抗原特異性を有するハイブリドーマ細胞のスクリーニング方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376170B1 (en) * 1994-10-03 2002-04-23 The Scripps Research Institute Ligand capture-directed selection of antibody
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
US20090137416A1 (en) * 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
JP2004525627A (ja) 2001-02-20 2004-08-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド モノクローナル抗体の迅速な産生
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2009131605A2 (en) 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
US20110275535A1 (en) 2008-12-16 2011-11-10 Novartis Ag Yeast Display Systems
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
SG11201908384XA (en) * 2017-03-24 2019-10-30 Lankenau Inst Medical Res Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520037A (ja) 2001-01-16 2004-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
US20110269152A1 (en) 2010-05-02 2011-11-03 Miltenyi Biotec Gmbh Anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell
JP2015536345A (ja) 2012-11-14 2015-12-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 組換え型の細胞表面捕捉タンパク質
US20150377887A1 (en) 2013-02-27 2015-12-31 Yu-Cheng Su In situ affinity maturation of antibodies
JP2016163574A (ja) 2015-03-06 2016-09-08 艾博生技抗体股▲ふん▼有限公司 抗原特異性を有するハイブリドーマ細胞のスクリーニング方法

Also Published As

Publication number Publication date
IL269472B2 (en) 2024-10-01
SG10202110530WA (en) 2021-11-29
IL312457A (en) 2024-06-01
WO2018175917A1 (en) 2018-09-27
US11946074B2 (en) 2024-04-02
EP3601558A1 (en) 2020-02-05
US20240191207A1 (en) 2024-06-13
US20200010810A1 (en) 2020-01-09
SG11201908384XA (en) 2019-10-30
EP3601558A4 (en) 2021-01-06
JP2020515288A (ja) 2020-05-28
CA3056249A1 (en) 2018-09-27
IL269472B1 (en) 2024-06-01
IL269472A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
Burnett et al. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability
JP6411329B2 (ja) 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
CN107973854B (zh) Pdl1单克隆抗体及其应用
Kwakkenbos et al. Stable long‐term cultures of self‐renewing B cells and their applications
JP7022067B2 (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
US20240191207A1 (en) Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
CN116640216B (zh) 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用
Kivi et al. HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
CN120842435A (zh) 抗hk2嵌合抗原受体(car)
CN116375867A (zh) 抗gprc5d抗体及其应用
CN110382548A (zh) 选择抗体的方法
Seydoux et al. Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
Olia et al. Anti-idiotype isolation of a broad and potent influenza A virus-neutralizing human antibody
Voigt et al. Therapeutic antibody discovery in infectious diseases using single-cell analysis
Abba Moussa et al. Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches
Challa et al. Function-first discovery of high affinity monoclonal antibodies using Nanovial-based plasma B cell screening
WO2023232110A1 (zh) 抗人cd24抗体及其应用
KR102536302B1 (ko) Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
WO2013030799A1 (en) B cell assay
TWI698643B (zh) 用於檢測米田堡血型抗原的抗體及其片段、試劑盒及方法
CN111876476A (zh) 用于扩增马抗体的巢式pcr引物、试剂盒及其应用
Zhai et al. Monoclonal Antibody Development Technology for Important Human Diseases
Marsman et al. Immune counter-evolution: immortalized B cell clones can undergo ex vivo directed evolution to counteract viral escape
US10995134B2 (en) Method for development of monoclonal antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230525

R150 Certificate of patent or registration of utility model

Ref document number: 7287940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150